ReviewNephrology (Carlton, Vic.)2023
Definitions, phenotypes, and subphenotypes in acute kidney injury-Moving towards precision medicine.
Review in Nephrology (Carlton, Vic.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Position statement of the Brazilian Society of Nephrology on the refusal and discontinuation of dialysis.Jornal brasileiro de nefrologiaGuideline
- Precision medicine in pediatric sepsis-associated acute kidney injury: when systemic heterogeneity meets organ-level heterogeneity.World journal of pediatrics : WJP · 2026Article
- Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.Blood advances · 2025Observational
- Emerging applications of nanotechnology in the treatment of acute kidney injury.Nanomedicine (London, England) · 2025Review
- Soluble urokinase receptor is a kidney-specific vasoconstrictor.EBioMedicine · 2025Article
- Exploring trajectories of acute kidney injury in the intensive care unit: a population-based cohort study.Scientific reports · 2025Article
- Epidemiology, trajectories and outcomes of acute kidney injury among hospitalized patients: a large retrospective multicenter cohort study.Journal of nephrology · 2025Article
- Observational
- Pathophysiological role of endothelial biomarkers inToxicon: X · 2025Article
- Persistent severe AKI is bad-where to go now?Intensive care medicine · 2025Article
- Metabolic and Microcirculatory Changes in Severe Renal Ischemia-Reperfusion and Ischemic Preconditioning in the Rat: Are They Detectable in the First Hour of Reperfusion?Life (Basel, Switzerland) · 2025Article
- Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers.Kidney international reports · 2025Article
- Framework for Kidney Health Follow-Up Among Neonates With Critical Cardiac Disease: A Report From the Neonatal Kidney Health Consensus Workshop.Journal of the American Heart Association · 2025Review
- The potential of neutrophil gelatinase-associated lipocalin in management of acute kidney injury and peritoneal dialysis-related peritonitis: a narrative review.Frontiers in nephrology · 2025Review
- Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement.Intensive care medicine · 2024Article
- Biomarkers in pursuit of precision medicine for acute kidney injury: hard to get rid of customs.Kidney research and clinical practice · 2024Article
- Neutrophil Gelatinase-Associated Lipocalin Cutoff Value Selection and Acute Kidney Injury Classification System Determine Phenotype Allocation and Associated Outcomes.Annals of laboratory medicine · 2023Article
- Precision management of acute kidney injury in the intensive care unit: current state of the art.Intensive care medicine · 2023Review
- Definitions, phenotypes, and subphenotypes in acute kidney injury-Moving towards precision medicine.Nephrology (Carlton, Vic.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The current definition of acute kidney injury (AKI) is generic and, based only on markers of function, is unsuitable for guiding individualized treatment. AKI is a complex syndrome with multiple presentations and causes. Targeted AKI management will only be possible if different phenotypes and subphenotypes of AKI are recognised, based on causation and related pathophysiology. Molecular signatures to identify subphenotypes are being recognised, as specific biomarkers reveal activated pathways. Assessment of individual clinical risk needs wider dissemination to allow identification of patients at high risk of AKI. New and more timely markers for glomerular filtration rate (GFR) are available. However, AKI diagnosis and classification should not be limited to GFR, but include tubular function and damage. Combining damage and stress biomarkers with functional markers enhances risk prediction, and identifies a population enriched for clinical trials targeting AKI. We review novel developments and aim to encourage implementation of these new techniques into clinical practice as a strategy for individualizing AKI treatment akin to a precision medicine-based approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.